One of the main challenges is the complexity of epigenetic regulation. The methylation status of CpG islands can vary widely between different types of cancer and even among patients with the same cancer type. Additionally, the dynamic nature of DNA methylation poses difficulties in consistently targeting these changes for therapeutic purposes.
